Genentech's Avastin is as effective in treating lung-cancer patients with half the drug's current recommended dose as it is using a full dose, according to a study conducted by parent company Roche Holdings Ltd. of Switzerland.
The study outcome means doctors could start prescribing the lower dose of Avastin, leading to a decline in the monthly price for Avastin to $4,400 from $8,800.
The study outcome means doctors could start prescribing the lower dose of Avastin, leading to a decline in the monthly price for Avastin to $4,400 from $8,800.
Insider's view: a real "D'oh!" moment when that trial's randomization code was broken! Bet the call from Roche to Genentech was a chilly one!
No comments:
Post a Comment